Research programme: HuMab 5B1 radioimmunotherapy - MabVax

Drug Profile

Research programme: HuMab 5B1 radioimmunotherapy - MabVax

Alternative Names: 177Lu-DTPA-HuMab-5B; HuMab 5B1 radioimmunotherapy agent - MabVax; HuMab-5B1 conjugated Actinium225-radioimmunotherapy agent; MVT 1075; radiolabeled HuMab 5B1 antibody - MabVax

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator MabVax Therapeutics
  • Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Antibodies; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Immunomodulators; Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pancreatic cancer

Most Recent Events

  • 23 Feb 2017 The US FDA approves IND application for MVT 1075 in Pancreatic cancer
  • 23 Feb 2017 Pharmacodynamics data from a preclinical trial in Pancreatic cancer released by MabVax Therapeutics
  • 09 Jan 2017 MabVax Therapeutics files an IND application with the FDA in USA for Pancreatic cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top